Department of Clinical Laboratory, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
Int J Biochem Cell Biol. 2013 Nov;45(11):2349-58. doi: 10.1016/j.biocel.2013.08.002. Epub 2013 Aug 19.
The metastasis suppressor CD82/KAI-1, which is a member of the tetraspanin superfamily, has been proposed to exert its activity together with glycosphingolipids. However, the mechanism of CD82 inhibition has not been fully elucidated. The present study aimed to investigate the synergistic inhibition of cell migration by the tetraspanin CD82 and gangliosides and to correlate this inhibition with activation of epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (HGFR/cMet) in Hepa1-6 cell lines, whose motility and migration is stimulated by epidermal growth factor (EGF) and hepatocyte growth factor (HGF) in vitro. We found that Hepa1-6 cells transfected with the CD82 gene exhibited decreased migration in response to EGF and HGF. EGF-stimulated phosphorylation of EGFR at Tyr1173 was inhibited in these cells, which contributed to the attenuation of EGFR. Ectopic expression of CD82 in Hepa1-6 cells inhibited HGF-stimulated tyrosine phosphorylation of cMet at Tyr1313 and Tyr1365 without affecting the expression of cMet. These inhibitory effects were enhanced when CD82 was introduced with Ganglioside GM3 alone or GM2/GM3. Reduction of CD82 expression by RNA interference together with depletion of glycosphingolipids with P4 significantly enhanced cell motility and increased the expression of EGFR and its phosphorylation at Tyr1173 in response to EGF. Increased cell motility and HGF-dependent activation of cMet at Tyr1313 and Tyr1365 resulted from decreased CD82 levels and increased GM3. Furthermore, CD82 expression selectively attenuated EGFR and cMet signalling via phosphatidylinositol 3-kinase/Akt but had no affect on the activity of the MAPK signalling pathway. These results suggest that the synergistic effects of CD82 and GM3 or GM2/GM3 on EGFR expression and phosphorylation and cMet activation are responsible for CD82 inhibition of EGF- and HGF-dependent cell motility and migration of Hepa1-6 cells.
肿瘤转移抑制因子 CD82/KAI-1 属于四跨膜蛋白超家族成员,其功能的发挥可能与糖脂有关。然而,CD82 抑制的机制尚未完全阐明。本研究旨在探讨四跨膜蛋白 CD82 与神经节苷脂联合抑制细胞迁移的作用,并探讨其与表皮生长因子受体(EGFR)和肝细胞生长因子受体(HGFR/cMet)激活的相关性。在 Hepa1-6 细胞系中,表皮生长因子(EGF)和肝细胞生长因子(HGF)可刺激细胞迁移和运动。我们发现,转染 CD82 基因的 Hepa1-6 细胞对 EGF 和 HGF 的迁移反应性降低。这些细胞中 EGF 刺激的 EGFR Tyr1173 磷酸化受到抑制,从而导致 EGFR 失活。在 Hepa1-6 细胞中过表达 CD82 可抑制 HGF 刺激的 cMet Tyr1313 和 Tyr1365 酪氨酸磷酸化,而不影响 cMet 的表达。当 CD82 与神经节苷脂 GM3 单独或 GM2/GM3 联合表达时,这些抑制作用增强。用 P4 耗尽糖脂可减少 RNA 干扰引起的 CD82 表达,增强细胞迁移,并增加对 EGF 的反应性,从而增加 EGFR 的表达及其 Tyr1173 磷酸化。CD82 水平降低和 GM3 增加导致细胞迁移增加和 HGF 依赖性 cMet Tyr1313 和 Tyr1365 激活。此外,CD82 表达通过磷酸肌醇 3-激酶/Akt 选择性地减弱 EGFR 和 cMet 信号转导,但对 MAPK 信号通路的活性没有影响。这些结果表明,CD82 与 GM3 或 GM2/GM3 的协同作用对 EGFR 表达和磷酸化以及 cMet 激活的影响是 CD82 抑制 Hepa1-6 细胞中 EGF 和 HGF 依赖性细胞迁移和运动的原因。